Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000907 · ClinicalTrials.gov registry record

A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients

A clinical trial of HIV Infections and Mycobacterium Avium-Intracellulare Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
50
Enrollment target
20
Study locations

NCT00000907: Completed study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00000907 is a study of HIV Infections and Mycobacterium Avium-Intracellulare Infection that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 50 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000907, a study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
50 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effects of stopping preventive therapy for DMAC in HIV-positive patients who (1) have been treated for DMAC for at least 12 months and are now free of any signs of DMAC for at least 16 weeks, and (2) have improved immune systems (CD4 cell counts greater than or equal to 100 cells/mm3) due to anti-HIV drug therapy. DMAC is a serious and sometimes life-threatening infection that usually affects only HIV-positive patients with CD4 cell counts (cells of the immune system that fight infection) less than 50 cells/mm3. It is recommended that people who are likely to get DMAC be placed on preventive medications which help reduce the risk of infection. New anti-HIV combination drug therapies can increase CD4 cell counts and can reduce the level of HIV in the blood. When CD4 counts are increased, risk of DMAC infection is less. This study examines whether it is possible to stop preventive therapy for DMAC when CD4 counts are high without placing individuals at risk for getting DMAC again.

Conditions Studied

HIV Infections Mycobacterium Avium-Intracellulare Infection

Study Locations (20)

California

  • Univ of Southern California / LA County USC Med Ctr - Los Angeles
  • Willow Clinic - Menlo Park
  • Univ of California / San Diego Treatment Ctr - San Diego
  • San Francisco AIDS Clinic / San Francisco Gen Hosp - San Francisco
  • San Francisco Gen Hosp - San Francisco
  • Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium - San Jose
  • San Mateo AIDS Program / Stanford Univ - Stanford
  • Stanford Univ Med Ctr - Stanford

New York

  • SUNY / Erie County Med Ctr at Buffalo - Buffalo
  • Beth Israel Med Ctr - New York
  • Bellevue Hosp / New York Univ Med Ctr - New York
  • Mount Sinai Med Ctr - New York

Indiana

  • Indiana Univ Hosp - Indianapolis
  • Division of Inf Diseases/ Indiana Univ Hosp - Indianapolis

Colorado

  • Univ of Colorado Health Sciences Ctr - Denver

Florida

  • Univ of Miami School of Medicine - Miami

Georgia

  • Emory Univ - Atlanta

Hawaii

  • Univ of Hawaii - Honolulu

Illinois

  • Rush Presbyterian - Saint Luke's Med Ctr - Chicago

Trial Details

FieldValue
Enrollment Target 50 participants
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00000907 record still lists

NCT00000907 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower).

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 0 interventions.

NCT00000907 names 20 study sites across 9 states, led by California, New York, Indiana.

Frequently Asked Questions

What is clinical trial NCT00000907 about?

NCT00000907 is a clinical study titled "A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients". The purpose of this study is to evaluate the effects of stopping preventive therapy for DMAC in HIV-positive patients who (1) have been treated for DMAC for at least 12 months and are now free of any signs of DMAC for at least 16 weeks, and (2) have improved immune systems (CD4 cell counts greater t...

What is the current status of trial NCT00000907?

This trial is currently completed. The enrollment target is 50 participants.

What conditions does trial NCT00000907 study?

This clinical trial studies the following conditions: HIV Infections, Mycobacterium Avium-Intracellulare Infection.

Who is sponsoring clinical trial NCT00000907?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000907 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00000907's enrollment target sits among peer trials

50 355th of 542 higher than 177 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Related registry views

Source: ClinicalTrials.gov NCT00000907, the US trial registry maintained by the National Library of Medicine. NCT00000907 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.